NCT06063590 - A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

November 28, 2024

Study Completion Date

April 1, 2025

Conditions

Aging Frailty

Interventions

BIOLOGICAL

StromaForte

100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min

Trial Locations (1)

Unknown

RECRUITING

Burjeel Medical City, Abu Dhabi